A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Conditions:   Small Cell Lung Cancer;   Neuroendocrine Carcinoma Interventions:   Drug: RO7616789;   Drug: Tocilizumab Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials